Etanercept
- Generic Name
- Etanercept
- Brand Names
- Enbrel, Eticovo, Benepali, Erelzi, Nepexto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 185243-69-0
- Unique Ingredient Identifier
- OP401G7OJC
- Background
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technolo...
- Indication
Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is al...
- Associated Conditions
- Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 752
- Registration Number
- NCT00245960
- Locations
- 🇩🇪
SCIderm GmbH Hamburg, Hamburg, Germany
🇩🇪Klinikum Innenstadt der Universitaet Muenchen, Muenchen, Germany
🇭🇺Medical University of Szeged, Szeged, Hungary
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
- Conditions
- Interventions
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 180
- Registration Number
- NCT00224874
- Locations
- 🇺🇸
DFCI/Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States
Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- John Byrd
- Target Recruit Count
- 36
- Registration Number
- NCT00201682
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 25
- Registration Number
- NCT00205231
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-12-06
- Target Recruit Count
- 27
- Registration Number
- NCT00201812
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-11-30
- Target Recruit Count
- 38
- Registration Number
- NCT00201838
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 720
- Registration Number
- NCT00195507
Study Investigating Enbrel Treatment for Ankylosing Spondylitis
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-09-16
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 526
- Registration Number
- NCT00195416
Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-06-18
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 1000
- Registration Number
- NCT00195377
Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00195338
- Locations
- 🇱🇺
Pfizer Investigational Site, Luxembourg, Luxembourg
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.